To assess whether adjunct exchange transfusion increases survival rates in comparison with antimalarial chemotherapy alone, among patients with severe falciparum malaria.
Assessment of study quality
Study quality was assessed using a scale developed by Downs and Black (see Other Publications of Related Interest no.1) for assessing the quality of non-randomised trials. The criteria included: statistical power; comparability of treatment groups; representativeness of treatment populations and modalities; adjustment for confounding; description of treatment group characteristics; interventions; and principal confounding variables. Two independent reviewers undertook the quality scoring process.
Data extraction
Two independent reviewers extracted the data.
Data were extracted on the year and country of publication, and the geographical region where the infections occurred. Data were also extracted on the following: the mean age of the patients in the treatment groups; their malaria immune status; the mean level of parasitaemia as a percentage; the mean number of WHO criteria for severe or complicated malaria that were met by the study patients; the antimalarial drug used; the criteria for performing exchange
Methods of synthesis
How were the studies combined? The studies were combined statistically in a meta-analysis. Summative ORs were calculated using the fixed-effect model of Mantel and Haenszel (see Other Publications of Related Interest no.2). Where patient-specific data were available, a secondary analysis was performed to assess the effect of exchange transfusion on the survival rate. This was carried out after adjusting between the study participant groups for level of parasitaemia, malaria immune status, and number of WHO severe malaria criteria met. For this secondary analysis, the data were analysed by logistic regression, both with and without analytic weights derived from the inverse of each study's variance (precision). Trend tests were based on the non-parametric extension of the Wilcoxon rank-sum test developed by Cuzick (see Other Publications of Related Interest no.3). Publication bias was assessed using the method described by Egger et al. (see Other Publications of Related Interest no.4).
How were differences between studies investigated?
Heterogeneity was assessed visually by a Galbraith plot and using a chi-squared test. Sensitivity analyses were also performed for quality score, year of publication, country of publication, continent of infection, and immune status for the treatment groups of each study.
Results of the review
Eight case-control studies (n=279) were included in the review Adjunct exchange transfusion: the summary OR for survival after adjunct exchange transfusion, compared with antimalarial chemotherapy alone, was 1.2 (95% CI: 0.7, 2.1). This indicated no benefit to the intervention, although patients treated with exchange transfusion had higher levels of parasitaemia (means: 22% versus 12%; P=0.0005) and met a higher number of WHO severe malaria criteria (means: 3.4 versus 2.4; P=0.005).
There was no evidence of heterogeneity among the trials, either visually via Galbraith plots or statistically with the chisquared test (P=0.4). There was no evidence of publication bias (P=0.6).
The results of the sensitivity analysis indicated that the review's results were not overly influenced by a single study. The regression analysis showed no differences when comparing the effect size of the included studies on the basis of year or country of publication, or quality score. Some of the heterogeneity was explained by the patients' malaria immunity status (P=0.007) and by the continent of infection (P=0.05). Three studies from Southeast Asia of patients with partial immunity favoured exchange transfusion.
Three of the four studies with nonimmune patients (2 from Africa and 2 where the continent was not reported) found no improvement in survival among those patients who received exchange transfusion. A subgroup analysis of studies with patients of partial immunity yielded an OR of 0.5 (95% CI: 0.2, 1.2), compared with an OR of 2.1 (95% CI: 0.9, 4.8) for nonimmune patients. This suggested that exchange transfusion might be more effective for people who have a partial immunity to malaria.
The patient-specific data analysis indicated that, with adjustment for initial level of parasitaemia, malaria immune status and number of WHO severe malaria criteria met, no significant benefit of exchange transfusion was found (OR 0.3, 95% CI: 0.1, 2.4). Patients who had elevated parasitaemia or who met a greater number of WHO severe malaria criteria were more likely to die. Patients with more than 30% peripheral parasitaemia had a four-fold increase in their odds of death (OR 4.5, 95% CI: 1.2, 16.8). Patients with more than four WHO severe malaria criteria had a five-fold increase in their odds of death (OR 5.3, 95% CI: 1.3, 21.7), with death more likely for every additional severe malaria criteria met (P<0.001) for trend.
